Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Sheep monoclonal antibodies maker Bioventix reported a fall in profit as higher costs and adverse foreign exchange movements weighed on performance.
For the year ended 30 June 2021, pre-tax profit fell 1% to £8.12 million as revenue increased 6% to £10.93 million year-on-year.
Profit was hurt by the adverse impact of foreign exchange movements and an increased charge in respect of share options issued in previous years.
The company declared a second interim dividend of 62 pence per share, up from 52 pence.
'Our most significant revenue stream continues to come from the vitamin D antibody called vitD3.5H10,' the company said.
'This antibody is used by a number of small, medium and large diagnostic companies around the world for use in vitamin D deficiency testing,' it added.
Sales of vitD3.5H10 remained relatively unchanged at £4.8 million during the year due to a 'flatter downstream market for vitamin D testing and pandemic effects.'